{
    "2021-10-28": [
        [
            {
                "time": "",
                "original_text": "欧普康视2021年三季报点评：业绩符合我们预期，OK镜龙头地位持续巩固【东吴医药朱国广团队】",
                "features": {
                    "keywords": [
                        "欧普康视",
                        "三季报",
                        "OK镜",
                        "龙头地位",
                        "业绩预期"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "华鑫证券维持欧普康视推荐评级：终端需求良好，业绩符合预期",
                "features": {
                    "keywords": [
                        "华鑫证券",
                        "欧普康视",
                        "推荐评级",
                        "终端需求",
                        "业绩预期"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}